Business Context and Reporting Period
This Form 8-K was filed by Pavmed Inc. on March 7, 2019. The company is incorporated in Delaware and identifies as an emerging growth company. The report details corporate governance actions regarding equity compensation plans and officer appointments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity plan amendments and option grants rather than financial performance metrics.
Material Changes
- Equity Plan Amendment: The Board approved an amendment to the 2014 Long-Term Incentive Equity Plan to increase the annual grant limit per participant from 195,108 shares to 10% of the total shares available under the Plan (currently 595,108 shares).
- Option Grants: The Compensation Committee approved the grant of ten-year stock options with an exercise price of $1.00 per share. These options vest in 12 equal quarterly installments starting March 31, 2019.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. It does not disclose specific risks, contingencies, or unusual items beyond the standard disclosure of the equity grants.
Important Facts for Investors to Verify
- Grant Recipients: Verify the specific individuals receiving options: David S. Battleman, M.D., David Weild IV, James L. Cox, M.D., Ronald M. Sparks (200,000 shares each), Michael J. Glennon (200,000 shares), and Brian J. deGuzman, M.D. (100,000 shares).
- Dilution Impact: Assess the potential dilution from the total 1,100,000 shares granted under this specific action.
- Exercise Price: Confirm the $1.00 exercise price relative to the current market price of Pavmed Inc. stock.
- Vesting Schedule: Note the 12-quarter vesting schedule commencing March 31, 2019.